Pluri was granted a new U.S. patent titled, “System and Methods for Immune Cells Expansion and Activation in Large Scale.” Pluri’s novel technology represents a paradigm shift in immune cell expansion methodologies because, unlike traditional approaches, its method employs a fundamentally different concept. Pluri’s proprietary 3D cell expansion technology mimics the natural lymph node like environment that immune cells have within the human body. The tightly controlled and fully automated bioreactor system provides cells with the conditions they need in order to expand, enabling efficient expansion of immune cells at scale and quality. This innovative approach ensures that the produced immune cells retain their integrity, functionality, and therapeutic efficacy, thus offering a promising solution to meet the escalating demand for advanced cell-based therapies for immune disorders and neurodegenerative diseases.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLUR:
- Pluri trading halted, news pending
- Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences
- Pluri announces leadership from business verticals to attend conferences
- Pluri Inc. Announces 1-for-8 Reverse Share Split
- Pluri announces 1-for-8 reverse stock split